Takeda Obtains Additional Indication and Dosage & Administration for ADCETRIS® as a Frontline Treatment for CD30-positive Hodgkin Lymphoma in Japan
(WorldNews Japan)

Osaka, Japan, September 21, 2018, --- Takeda Pharmaceutical Company Limited, (`Takeda`) (TSE:4502) announced today that it has obtained an additional indication and dosage & administration for the use of ADCETRIS® (brentuximab vedotin; `ADCETRIS`) in combination with doxorubicin, vinblastine and dacarbazine as a frontline treatment option for CD30-positive Hodgkin lymphoma